Lipoplex-based targeted gene therapy for the suppression of tumours with VEGFR expression by producing anti-angiogenic molecules

BACKGROUND: The anti-angiogenic fusion protein RBDV-IgG1 Fc (RBDV), which comprises the receptor-binding domain of vascular endothelial growth factor-A (VEGF-A), has shown antitumour effects by reducing angiogenesis in vivo. This study used the cationic lipoplex lipo-PEG-PEI-complex (LPPC) to simult...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Shu-Yi, Chen, Pin-Rong, Chen, Chia-Hung, Tsai, Nu-Man, Lin, Yu-Hsin, Lin, Chen-Si, Chuang, Cheng-Hsun, Huang, Xiao-Fan, Chan, Yi-Lin, Liu, Yen-Ku, Chung, Chen-Han, Weng, Shun-Long, Liao, Kuang-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144055/
https://www.ncbi.nlm.nih.gov/pubmed/32272948
http://dx.doi.org/10.1186/s12951-020-00610-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144055/
https://www.ncbi.nlm.nih.gov/pubmed/32272948
http://dx.doi.org/10.1186/s12951-020-00610-9

Ejemplares similares